The first inhibitors of oncogenic HH—GLI that were approved by the FDA for the treatment of advanced and metastatic basal cell carcinoma (BCC) were the small molecule SMO inhibitors (SMOi), vismodegib and sonidegib [18,19,20,21,22]. The gene discussed is GLI1; the disease is skin basal cell carcinoma.